PTU-68 the Expression and Clinical Significance of MLN64 in Human Pancreatic Cancer

Laijian Sui,Lin Ye,Chunyi Hao,Yuxin Cui,Ke Ji,Jiafu Ji,Wen G Jiang
DOI: https://doi.org/10.1136/gutjnl-2021-bsg.270
2021-01-01
Abstract:Introduction Aberration of MLN64 (Metastatic Lymph Node Protein 64), also known as StARD3 (StAR Related Lipid Transfer Domain Containing 3), has been reported in endocrine related cancers including breast and prostate cancers and found to be present in insulinoma cells. The present study evaluated the clinical and prognostic values of MLN64 to clarify its role in human pancreatic cancer. Methods Human pancreatic cancer cell lines, PANC1 and MIA PaCa-2 were used. The levels of MLN64 gene transcripts were quantitatively evaluated in a cohort of human pancreatic cancer with matched normal tissues. The expression of the transcripts were evaluated against the clinical, pathological and outcome parameters of the patients. Results Pancreatic cancer tissues had a markedly increased levels of MLN64 (Median (Q1-Q3)): 4.85 (0-61) compared with normal tissues (0.03 (0-7.6)) (p<0.001). It was also revealed that MLN64 in tumours of patients who died of pancreatic cancer during the followup period had a significantly highly levels of MLN64 (7.66 (0-20)), compared with those who survived (0.02 (0-72.5)) (p<0.01), further indicating MLN64 as a significant prognostic factor (HR 8.37, p<0.01). Our data also revealed node positive pancreatic tumours had a significantly higher levels of MLN64 than node negative tumours (p<0.05), although no significant difference was seen between those with distant metastases and those without. Significant correlation was also found between MLN64 and the Her family members, namely Her4 (p<0.001) and Her3 (p<0.05) and that the combining the pattern of expression of MLN64 and Her4 further enhance the power in predicting outcomes of the patients. Using our pancreatic cancer cell models, we have demonstrated that blocking Her family kinases using a pan-Her inhibitor, namely Nerlynx and a key cell migration regulator, phospholipase C-gamma1 (PLCγ1), had a marked impact on cellular migration and adhesion of pancreatic cancer cells, key functions observed with MLN64 in cancer cells. Conclusions MLN64/StARD3, one of the key regulators of cancer cells, has an aberrant expression in human pancreatic cancer which is linked to the clinical outcome. With its role in cancer cells and discovery of inhibitory means to MLN64/StARD3, the molecule presents a good target for therapeutic considerations in pancreatic cancer.
What problem does this paper attempt to address?